Objectives-To assess the incidence and significance of anticardiolipin antibodies after myocardial infarction and in unstable angina.
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An association between raised concentrations of anticardiolipin antibodies and recurrent arterial and venous thrombosis was first suggested in 1983.' Subsequently two studies have reported an association between raised concentrations of antibodies and myocardial infarction.2' Also, an association was found between raised concentrations of anticardiolipin antibodies and failure of coronary artery bypass grafts. 4 Other studies report an association between anticardiolipin antibodies and arterial and venous thrombosis in other sites, mostly in patients with autoimmune disorders. 56 These antibodies are part of a family of antibodies to negatively charged phospholipids and are also related to the lupus anticoagulant. 5 Phospholipids are important in the coagulation cascade as well as being components of endothelial cell walls and platelets. 5 It is an attractive concept that antibodies against phospholipids may be associated with ischaemic heart disease in patients without overt autoimmune disorders.
Hamsten and M5),8 and antismooth muscle antibody. Cardiac enzymes were measured on days 1, 2, and 3. All surviving patients were reviewed in the cardiac out patient clinic at five weeks, five months, and 12 months after myocardial infarction with a full history, clinical examination, electrocardiogram, and anticardiolipin antibody estimations.
Five patients who lived outside the district were not followed up and two patients dropped out from follow up. Standard treatment included streptokinase, intravenous heparin for the first 24 hours, and 150 to 300 mg of aspirin daily where appropriate.
The unstable angina group consisted of 99 men and 61 women (160), median age 52 (men 51, women 52). The diagnosis was based on a history of prolonged cardiac pain without electrocardiographic or enzyme changes associated with infarction. Anticardiolipin antibodies were estimated on day 1 with the same routine investigations and autoimmune screen. Standard treatment included 150 to 300 mg of aspirin daily. The angina patients were not followed up for the purpose of this study.
Serum samples from age and sex matched controls were taken from a group of 504 normal people (blood donors or patients attending the pathology department for a routine biochemical screening with no history of ischaemic heart disease). DETECTION 
There was no significant association between the presence of anticardiolipin antibodies and major cardiovascular risk factors including previous myocardial infarction or angina.
During follow up there was an apparent increase in the percentage of patients with raised IgG (with a peak at five months) but this did not reach significance. The percentage of patients with raised IgM did not change over the 12 month follow up period.
Other autoantibodies There was no significant association between the presence of antinuclear factor, antismooth muscle, antibodies to M2 or M5 and anticardiolipin antibody concentrations at any time. The only patient with systemic lupus erythematosus had an antinuclear factor of 1:160 on admission, and an IgG of 23 GPL units and IgM of 13 MPL units at five weeks.
Complications
In the seven patients who died in hospital and the 12 who died during follow up there was no significant association with anticardiolipin antibody concentrations. Similarly, there was no association with further myocardial infarction: nine patients had a second myocardial infarction in hospital and 19 had a further myocardial infarction during follow up.
Analysis of patients' highest IgG (at any time) subdivided into low and medium positive, failed to show a difference between the patients who did and did not have adverse 
